目的:观察中药制剂蒲地蓝消炎口服液对流行性角结膜炎的临床疗效及安全性。方法:采用随机、双盲、平行对照的方法,将120例226眼流行性角结膜炎患者随机分为试验组和对照组,每组各60例。试验组应用蒲地蓝消炎口服液联合双氯芬酸钠滴眼液进行治疗,对照组应用双氯芬酸钠滴眼液治疗,总疗程为14d,观察两组用药后的临床疗效及其安全性指标。结果:试验组和对照组的临床疗效总有效率分别为90.0%和75.0%,痊愈率分别为85.0%和68.3%,差异有统计学意义(P<0.05),试验组和对照组均无明显不良反应。结论:蒲地蓝消炎口服液联合双氯芬酸钠滴眼液与单纯使用双氯芬酸钠滴眼液相比,其治疗流行性角结膜炎的临床疗效确切,无不良反应。

·AIM:To observe the efficacy and safety of oral anti-inflammatory drug pudilan for epidemic keratoconjunctivitis.METHODS:A total of 120 cases 226 eyes with epidemic keratoconjunctivitis were randomly divided into test group and control group,60 cases in each group.The test group was treated with pudilan oral liquid and diclofenac sodium eye drops;the control group received diclofenac sodium eye drops,for 14 days as a total course of treatment.Clinical efficacy and safety were observed after treatment.RESULTS:In the test group and control group,the total clinical effective rates were 90.0% and 75.0%,the cure rates were 85.0% and 68.3% respectively,the difference was statistically significant(P<0.05).The test group and control group had no significant adverse reactions.CONCLUSION:Compared with simple use of diclofenac sodium eye drops,pudilan oral liquid combined with diclofenac sodium eye drops has exact clinical curative effect and no adverse reaction in treatment of epidemic keratoconjunctivitis.

R276.7